CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

Sponsor
Canadian Cancer Trials Group
Study ID
NCT04176848
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CFI-400945 — DRUG
    CFI-400945 32 mg: Cycle 1: Days 1-7, then Days 15-21; Cycle 2 on: orally once daily
  • Durvalumab — DRUG
    Cycle 2 on: Durvalumab 1500mg IV on Day 1 (28 day cycles)

Study Details

The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer.

Key Dates

Start date
Aug 10, 2020
Status verified
Sep 2025
Primary completion
Sep 15, 2022
Completion
Dec 31, 2026

Study Design

Enrollment
15 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CFI-400945 + Durvalumab
    CFI-400945 32 mg orally on Days 1-7 and Days 15-21 of Cycle 1 (28 day cycle) and then daily from Cycle 2 on and Durvalumab 1500mg IV on Day 1 (28 day cycles) from Cycle 2 on.

Primary Outcome Measure

Objective Response Rate [ Time Frame: 24 months ]

Related Studies